RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment

Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Said, Neveen, Theodorescu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494636/
https://www.ncbi.nlm.nih.gov/pubmed/23170270
http://dx.doi.org/10.4161/onci.20594
_version_ 1782249420025233408
author Said, Neveen
Theodorescu, Dan
author_facet Said, Neveen
Theodorescu, Dan
author_sort Said, Neveen
collection PubMed
description Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and creation of an inflammatory lung environment involving macrophages and the CCL2/CCR2 signaling axis. Targeting this mechanism may provide novel adjuvant strategies for delaying the appearance of clinical metastasis.
format Online
Article
Text
id pubmed-3494636
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34946362012-11-20 RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment Said, Neveen Theodorescu, Dan Oncoimmunology Author's View Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and creation of an inflammatory lung environment involving macrophages and the CCL2/CCR2 signaling axis. Targeting this mechanism may provide novel adjuvant strategies for delaying the appearance of clinical metastasis. Landes Bioscience 2012-10-01 /pmc/articles/PMC3494636/ /pubmed/23170270 http://dx.doi.org/10.4161/onci.20594 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Said, Neveen
Theodorescu, Dan
RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment
title RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment
title_full RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment
title_fullStr RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment
title_full_unstemmed RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment
title_short RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment
title_sort rhogdi2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494636/
https://www.ncbi.nlm.nih.gov/pubmed/23170270
http://dx.doi.org/10.4161/onci.20594
work_keys_str_mv AT saidneveen rhogdi2suppressesbladdercancermetastasisviareductionofinflammationinthetumormicroenvironment
AT theodorescudan rhogdi2suppressesbladdercancermetastasisviareductionofinflammationinthetumormicroenvironment

Ejemplares similares